199 related articles for article (PubMed ID: 32331228)
1. Immunoproteasome Genes Are Modulated in CD34
Di Rosa M; Giallongo C; Romano A; Tibullo D; Li Volti G; Musumeci G; Barbagallo I; Imbesi R; Castrogiovanni P; Palumbo GA
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331228
[TBL] [Abstract][Full Text] [Related]
2. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.
Tognon R; Gasparotto EP; Neves RP; Nunes NS; Ferreira AF; Palma PV; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Simões BP; de Souza AM; Castro FA
J Hematol Oncol; 2012 Feb; 5():2. PubMed ID: 22300941
[TBL] [Abstract][Full Text] [Related]
4. JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.
Catarsi P; Rosti V; Morreale G; Poletto V; Villani L; Bertorelli R; Pedrazzini M; Zorzetto M; Barosi G;
PLoS One; 2015; 10(1):e0116636. PubMed ID: 25617626
[TBL] [Abstract][Full Text] [Related]
5. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
[TBL] [Abstract][Full Text] [Related]
6. Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity.
Abbà C; Campanelli R; Catarsi P; Villani L; Abbonante V; Sesta MA; Barosi G; Rosti V; Massa M
PLoS One; 2019; 14(8):e0220189. PubMed ID: 31369569
[TBL] [Abstract][Full Text] [Related]
7. Distinct profile of CD34
Forte D; Barone M; Morsiani C; Simonetti G; Fabbri F; Bruno S; Bandini E; Sollazzo D; Collura S; Deregibus MC; Auteri G; Ottaviani E; Vianelli N; Camussi G; Franceschi C; Capri M; Palandri F; Cavo M; Catani L
J Exp Clin Cancer Res; 2021 Feb; 40(1):49. PubMed ID: 33522952
[TBL] [Abstract][Full Text] [Related]
8. JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan.
Sultan S; Irfan SM
Asian Pac J Cancer Prev; 2015; 16(17):7889-92. PubMed ID: 26625816
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
10. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
[TBL] [Abstract][Full Text] [Related]
11. Comparison of JAK2
Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
[TBL] [Abstract][Full Text] [Related]
12. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
13. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
[TBL] [Abstract][Full Text] [Related]
14. Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis.
Rossi C; Zini R; Rontauroli S; Ruberti S; Prudente Z; Barbieri G; Bianchi E; Salati S; Genovese E; Bartalucci N; Guglielmelli P; Tagliafico E; Rosti V; Barosi G; Vannucchi AM; Manfredini R;
Mol Oncol; 2018 Dec; 12(12):2102-2123. PubMed ID: 30259659
[TBL] [Abstract][Full Text] [Related]
15. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
[TBL] [Abstract][Full Text] [Related]
16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
17. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
Barosi G; Poletto V; Massa M; Campanelli R; Villani L; Bonetti E; Viarengo G; Catarsi P; Klersy C; Rosti V
PLoS One; 2013; 8(3):e59791. PubMed ID: 23555782
[TBL] [Abstract][Full Text] [Related]
18. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
[TBL] [Abstract][Full Text] [Related]
19. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
20. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
